EWM
ALNY icon

Executive Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Executive Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-140
Closed -$10K – 155
2019
Q2 		$10K Hold
140
– – ﹤0.01% 603
2019
Q1 		$13K Hold
140
– – ﹤0.01% 496
2018
Q4 		$10K Buy
+140
New +$10.8K ﹤0.01% 563

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Executive Wealth Management's ALNY Position: Q3 2019 in Review

Executive Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2019, closing a stake of 140 shares — an estimated $10K sold.

Executive Wealth Management first reported a position in ALNY in Q4 2018 and held it in 3 quarters. The position peaked at $13K in Q1 2019. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

  • Executive Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Executive Wealth Management sold 140 Alnylam Pharmaceuticals shares in Q3 2019, an estimated $10K.
  • Executive Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Executive Wealth Management's Alnylam Pharmaceuticals position peaked at $13K in Q1 2019.
  • 281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Executive Wealth Management's 13F filing for Q3 2019, filed 30 Oct 2019.